|Mr. Luc Tanguay||Pres, CEO & Non-Independent Director||762.95k||N/A||1958|
|Mr. Philippe Dubuc MBA||Sr. VP & CFO||433.21k||N/A||1967|
|Mr. Jocelyn Lafond||VP of Legal Affairs & Corp. Sec.||352.06k||N/A||1968|
|Mr. Denis Boucher B.A., L.L.B.||VP of Communications & Corp. Affairs||260.52k||N/A||1966|
|Mr. Christian Marsolais||Sr. VP & Chief Medical Officer||419.17k||N/A||1963|
Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States. The company was founded in 1993 and is headquartered in Montreal, Canada.
Theratechnologies Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 9; Compensation: 9.